As Alzheimer's disease treatment enters the era of disease-modifying therapy, clinicians face a pressing new challenge: not whether a drug works on average, but how to identify which patients benefit most — and how quickly. A blood-based biomarker capable of answering that question at the individual level would reshape how lecanemab is deployed in routine care.
This prospective real-world study enrolled 153 patients with early Alzheimer's disease receiving lecanemab and tracked plasma phosphorylated tau 217 (p-tau217) across multiple time points. P-tau217 concentrations declined significantly by three months into treatment, with the steepest reduction occurring between months three and six before reaching a plateau. Critically, patients were not uniform in their response: cluster analysis identified two distinct trajectory groups, and those with greater p-tau217 reduction showed meaningfully slower cognitive decline as measured by Clinical Dementia Rating-Sum of Boxes scores. Hypertension emerged as a baseline factor associated with a blunted biomarker response — a clinically relevant comorbidity given its prevalence in the early Alzheimer's population.
This work adds meaningful granularity to an already encouraging biomarker story. P-tau217 has rapidly ascended as the most diagnostically precise plasma tau species, and its use as a pharmacodynamic readout — reflecting real-time drug action rather than just disease presence — is an important conceptual step. The three-to-six-month window identified here as the period of greatest flux aligns with emerging mechanistic understanding of amyloid clearance kinetics under anti-amyloid antibody treatment. The hypertension finding warrants serious follow-up: if vascular co-pathology limits both tau response and cognitive benefit, stratifying patients by cardiovascular risk before initiating costly and logistically demanding infusion therapy could improve treatment efficiency. The study's real-world design strengthens generalizability but limits causal inference, and 153 patients, while meaningful for biomarker subgroup analysis, remains modest. Independent replication in larger cohorts is needed before p-tau217 trajectory formally enters treatment decision algorithms. Nonetheless, this represents incremental but directionally important progress toward personalized Alzheimer's therapeutics.